Archive - Progressions: A deep look at prostate cancer

Meet the androgen receptor

Testosterone's cancer overlord

Nov 22, 2024 •

October 2024

Am I dying, or aren’t I?

How much to trust a medical test

Oct 21, 2024 •

December 2023

Hazard ratios clarified

An amendment to the previous post

Dec 9, 2023 •

It just don’t work on you

How to interpret a hazard ratio

Dec 6, 2023 •

April 2023

Genes? Chromosomes? DNA?

How they fit together

Apr 23, 2023 •

January 2023

Caught in the Akt

Trial drug capivasertib blocks a notorious cancer pathway

Jan 24, 2023 •

August 2022

Your tumor’s mug shot

Prostate cancer under the microscope

Aug 12, 2022 •

The gland you left behind

What your prostate did when it was doing what it was supposed to be doing

Aug 10, 2022 •

June 2022

Down-to-earth microsatellite instability

What it is, what it means, and what's with the name

Jun 17, 2022 •

May 2022

Show me the PSMA

Part 1 of a series on its who, what, when, and where

May 19, 2022 •

Where cancer gets the nerve

Professor Moriarty will see you now

May 7, 2022 •

April 2022

They call me vipivotide tetraxetan

How PSMA-617 got its new name

Apr 12, 2022 •

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts